<DOC>
	<DOC>NCT01049217</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of pregabalin compared to placebo in reducing neuropathic pain associated with HIV neuropathy.</brief_summary>
	<brief_title>Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy</brief_title>
	<detailed_description>Based on DMC interim efficacy analysis results indicating a low probability for success the study was terminated on April 2, 2012; the termination was unrelated to any safety findings that could impact patient health.</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Men and women, ages of 18 or greater Documented evidence of HIV1 infection Documented diagnosis of HIVassociated Distal Symmetrical Polyneuropathy (DSP) with subjective sensory symptom of pain Pain starts in the feet Subject has untreated vitamin B12 deficiency (serum B12 level &lt;200 pg/ml) or if treated B12 deficiency treatment is less than 6 months of B12 supplementation (injection or intranasal B12) prior to screening Diabetes mellitus requiring regular medical treatment (other than diet and exercise) or HbA1C &gt;6.9 Subjects with peripheral neuropathic pain that is not associated with HIV infection; including subjects with conditions such as: Post Herpetic Neuralgia (PHN), Diabetic Peripheral Neuropathy (DPN), familial neuropathies; compression related neuropathy, radicular pain, other infection related neuropathies (eg, leprosy); neuropathy related to: metabolic abnormalities; nutritional factors; vascular insults; inflammation; autoimmune disease; and malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>neuropathy</keyword>
	<keyword>pain</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Infections</keyword>
</DOC>